Targeting Aberrant Epigenetic Networks Mediated by PRMT1 and KDM4C in Acute Myeloid Leukemia

Summary Transcriptional deregulation plays a major role in acute myeloid leukemia, and therefore identification of epigenetic modifying enzymes essential for the maintenance of oncogenic transcription programs holds the key to better understanding of the biology and designing effective therapeutic strategies for the disease. Here we provide experimental evidence for the functional involvement and therapeutic potential of targeting PRMT1, an H4R3 methyltransferase, in various MLL and non-MLL leukemias. PRMT1 is necessary but not sufficient for leukemic transformation, which requires co-recruitment of KDM4C, an H3K9 demethylase, by chimeric transcription factors to mediate epigenetic reprogramming. Pharmacological inhibition of KDM4C/PRMT1 suppresses transcription and transformation ability of MLL fusions and MOZ-TIF2, revealing a tractable aberrant epigenetic circuitry mediated by KDM4C and PRMT1 in acute leukemia.

[1]  O. Abdel-Wahab,et al.  The role of mutations in epigenetic regulators in myeloid malignancies , 2012, Nature Reviews Cancer.

[2]  S. Lowe,et al.  RNAi screen identifies Brd4 as a therapeutic target in acute myeloid leukaemia , 2011, Nature.

[3]  B. Porse,et al.  shRNA screening identifies JMJD1C as being required for leukemia maintenance. , 2014, Blood.

[4]  R. Roeder,et al.  Ordered Cooperative Functions of PRMT1, p300, and CARM1 in Transcriptional Activation by p53 , 2004, Cell.

[5]  M. Rosenfeld,et al.  Chem-seq permits identification of genomic targets of drugs against androgen receptor regulation selected by functional phenotypic screens , 2014, Proceedings of the National Academy of Sciences.

[6]  Yonghong Xiao,et al.  Selective killing of mixed lineage leukemia cells by a potent small-molecule DOT1L inhibitor. , 2011, Cancer cell.

[7]  Paola Fazi,et al.  Retinoic acid and arsenic trioxide for acute promyelocytic leukemia. , 2013, The New England journal of medicine.

[8]  B. Ponder,et al.  Dysregulation of PRMT1 and PRMT6, Type I arginine methyltransferases, is involved in various types of human cancers , 2011, International journal of cancer.

[9]  M. Stephens,et al.  RNA-seq: an assessment of technical reproducibility and comparison with gene expression arrays. , 2008, Genome research.

[10]  O. Abdel-Wahab,et al.  Mutations in epigenetic modifiers in the pathogenesis and therapy of acute myeloid leukemia. , 2013, Blood.

[11]  Yi Zhang,et al.  hDOT1L Links Histone Methylation to Leukemogenesis , 2005, Cell.

[12]  C. So,et al.  Retroviral/Lentiviral transduction and transformation assay. , 2009, Methods in molecular biology.

[13]  Juri Rappsilber,et al.  The putative oncogene GASC1 demethylates tri- and dimethylated lysine 9 on histone H3 , 2006, Nature.

[14]  I. Issaeva,et al.  UTX and JMJD3 are histone H3K27 demethylases involved in HOX gene regulation and development , 2007, Nature.

[15]  Pablo Tamayo,et al.  Gene set enrichment analysis: A knowledge-based approach for interpreting genome-wide expression profiles , 2005, Proceedings of the National Academy of Sciences of the United States of America.

[16]  T. Kouzarides.  Chromatin Modifications and Their Function , 2007, Cell.

[17]  C. So,et al.  Overcoming treatment resistance in acute promyelocytic leukemia and beyond , 2013, Oncotarget.

[18]  Zhen-yi Wang,et al.  Acute promyelocytic leukemia: from highly fatal to highly curable. , 2008, Blood.

[19]  I. Flinn,et al.  Ponatinib in refractory Philadelphia chromosome-positive leukemias. , 2012, The New England journal of medicine.

[20]  T. Jenuwein,et al.  Cooperative demethylation by JMJD2C and LSD1 promotes androgen receptor-dependent gene expression , 2007, Nature Cell Biology.

[21]  A T Look,et al.  Oncogenic transcription factors in the human acute leukemias. , 1997, Science.

[22]  C. So,et al.  Transcriptional and epigenetic networks in haematological malignancy , 2011, FEBS letters.

[23]  Tim J. Wigle,et al.  A selective inhibitor of EZH2 blocks H3K27 methylation and kills mutant lymphoma cells. , 2012, Nature chemical biology.

[24]  W. Huber,et al.  Moderated estimation of fold change and dispersion for RNA-seq data with DESeq2 , 2014, Genome Biology.

[25]  M. Cleary,et al.  Protein arginine-methyltransferase-dependent oncogenesis , 2007, Nature Cell Biology.

[26]  A. Scorilas,et al.  Clinical evaluation of PRMT1 gene expression in breast cancer , 2011, Tumor Biology.

[27]  Amanda J. Wilson,et al.  Synthetic lethal targeting of oncogenic transcription factors in acute leukemia by PARP inhibitors , 2015, Nature Network Boston.

[28]  Paul Theodor Pyl,et al.  HTSeq—a Python framework to work with high-throughput sequencing data , 2014, bioRxiv.

[29]  Jin He,et al.  KDM2b/JHDM1b, an H3K36me2-specific demethylase, is required for initiation and maintenance of acute myeloid leukemia. , 2011, Blood.

[30]  Kristian Helin,et al.  The Demethylase JMJD2C Localizes to H3K4me3-Positive Transcription Start Sites and Is Dispensable for Embryonic Development , 2014, Molecular and Cellular Biology.

[31]  Cole Trapnell,et al.  TopHat2: accurate alignment of transcriptomes in the presence of insertions, deletions and gene fusions , 2013, Genome Biology.

[32]  K. Helin,et al.  Erasing the methyl mark: histone demethylases at the center of cellular differentiation and disease. , 2008, Genes & development.

[33]  S. Lazic,et al.  Common and overlapping oncogenic pathways contribute to the evolution of acute myeloid leukemias. , 2011, Cancer research.

[34]  R. Campbell,et al.  Cancer epigenetics drug discovery and development: the challenge of hitting the mark. , 2014, The Journal of clinical investigation.

[35]  Yeon-Hee Lim,et al.  Effects of a novel arginine methyltransferase inhibitor on T‐helper cell cytokine production , 2010, The FEBS journal.

[36]  S. Robson,et al.  Inhibition of BET recruitment to chromatin as an effective treatment for MLL-fusion leukaemia , 2011, Nature.

[37]  Karl Mechtler,et al.  Loss of the Suv39h Histone Methyltransferases Impairs Mammalian Heterochromatin and Genome Stability , 2001, Cell.

[38]  Howard Y. Chang,et al.  Hierarchical maintenance of MLL myeloid leukemia stem cells employs a transcriptional program shared with embryonic rather than adult stem cells. , 2009, Cell stem cell.

[39]  A. Iwama,et al.  MOZ is essential for maintenance of hematopoietic stem cells. , 2006, Genes & development.

[40]  H. Stein,et al.  Oncogene-induced senescence as an initial barrier in lymphoma development , 2005, Nature.

[41]  Yan Liu,et al.  EZH2 inhibition as a therapeutic strategy for lymphoma with EZH2-activating mutations , 2012, Nature.

[42]  T. Brümmendorf,et al.  Current aspects in resistance against tyrosine kinase inhibitors in chronic myelogenous leukemia. , 2014, Drug discovery today. Technologies.

[43]  Christian Steidl,et al.  Cooperative epigenetic modulation by cancer amplicon genes. , 2010, Cancer cell.

[44]  Kristian Helin,et al.  The histone demethylase PHF8 governs retinoic acid response in acute promyelocytic leukemia. , 2013, Cancer cell.

[45]  G. Mufti,et al.  SnapShot: Acute myeloid leukemia. , 2012, Cancer cell.

[46]  Stuart Maudsley,et al.  VennPlex–A Novel Venn Diagram Program for Comparing and Visualizing Datasets with Differentially Regulated Datapoints , 2013, PloS one.

[47]  Tae Funakoshi,et al.  A novel noninvasive model of endometriosis for monitoring the efficacy of antiangiogenic therapy. , 2006, The American journal of pathology.

[48]  Z. Weng,et al.  The H3K4-Methyl Epigenome Regulates Leukemia Stem Cell Oncogenic Potential. , 2015, Cancer cell.

[49]  M. J. van de Vijver,et al.  Genomic amplification and oncogenic properties of the GASC1 histone demethylase gene in breast cancer , 2009, Oncogene.

[50]  I. Weissman,et al.  MLL-GAS7 transforms multipotent hematopoietic progenitors and induces mixed lineage leukemias in mice. , 2003, Cancer cell.

[51]  M. Cleary,et al.  Dimerization contributes to oncogenic activation of MLL chimeras in acute leukemias. , 2003, Cancer cell.

[52]  C. So,et al.  Identification and characterization of hematopoietic stem and progenitor cell populations in mouse bone marrow by flow cytometry. , 2009, Methods in molecular biology.

[53]  M. Baccarani,et al.  Hematologic and cytogenetic responses to imatinib mesylate in chronic myelogenous leukemia. , 2002, The New England journal of medicine.

[54]  John R Yates,et al.  PRMT1 interacts with AML1-ETO to promote its transcriptional activation and progenitor cell proliferative potential. , 2011, Blood.

[55]  Tony Pawson,et al.  WW Domains Provide a Platform for the Assembly of Multiprotein Networks , 2005, Molecular and Cellular Biology.

[56]  K. Akashi,et al.  MOZ-TIF2, but not BCR-ABL, confers properties of leukemic stem cells to committed murine hematopoietic progenitors. , 2004, Cancer cell.

[57]  C. So,et al.  Epigenetics in acute promyelocytic leukaemia pathogenesis and treatment response: A TRAnsition to targeted therapies , 2014, British Journal of Cancer.